China Pharma Holdings was given SFDA approval for Omeprazole Sodium injection, a proton pump inhibitor that is prescribed for gastroesophageal reflux disease (GERD) and other conditions caused by excessive stomach acid. The drug is a generic form of Losec and Prilosec, marketed by AstraZeneca. Although most Omeprazole products are oral, China Pharma’s formulation is an injection, which enters the blood circulation more quickly and avoids degradation in the stomach. More details...

Stock Symbol: (OTCBB: CPHI) (NYSE: AZN)